EZH-302 Symphony-1: estudio de fase 1b/3, doble ciego, aleatorizado, controlado con fármaco activo, de tres etapas y adaptativo en cuanto a biomarcadores, de tazemetostat o placebo en combinación con lenalidomida más rituximab en sujetos con linfoma folicular recidivante/refractario.
The participants of this study would have relapsed/refractory follicular lymphoma.
Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no longer works.
Stage 1 of this trial will study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for stage 2 and 3. Stage 1 of the study is completed.
Stages 2 and 3 will evaluate and compare how long participants live without their disease getting worse when receiving the study drug in combination with other drug treatment versus the placebo (dummy drug) in combination with other drug treatment.
